Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff

Bhupesh Parashar; A. Gabriella Wernicke; Al Pavese; Prabhsimranjot Singh; Samuel Trichter; Albert Sabbas; David I. Kutler; William Kuhel; Jeffery L. Port; Paul C. Lee; Dattatreyudu Nori; K. S.Clifford Chao

doi:10.1016/j.brachy.2011.04.002

Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff

Bhupesh Parashar, A. Gabriella Wernicke, Al Pavese, Prabhsimranjot Singh, Samuel Trichter, Albert Sabbas, David I. Kutler, William Kuhel, Jeffery L. Port, Paul C. Lee, Dattatreyudu Nori, K. S.Clifford Chao

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Purpose: Cesium-131 ( ¹³¹Cs) radioactive seed is Food and Drug Administration approved for permanent seed implant for all cancers, including lung and head and neck (HN) cancers. We describe the first clinical report of ¹³¹Cs dosimetry and exposure rates to treating physicians and staff. Methods and Materials: Twenty-eight patients received ¹³¹Cs implant for early stage lung and recurrent HN cancers. A nomogram was developed to calculate the number of seeds needed to cover the wedge line with the prescription dose (80Gy). Final dosimetry was obtained after CT planning a few days following the surgical procedure. Radiation exposure to the treating physicians and staff was measured at the completion of the procedure. Results: A nomogram was developed using the variseed software with source data from American Association of Physicists in Medicine TG-43 report. The total volume covered by the prescription isodose line of ¹³¹Cs was measured and compared with ¹²⁵I. The prescription volume was smaller for ¹³¹Cs. In addition, the exposure rate with ¹³¹Cs was found to be acceptable. Conclusion: Our preliminary experience with ¹³¹Cs lung and HN brachytherapy has been very encouraging with excellent dosimetric coverage and acceptable exposure to the treating physicians and staff.

Original language	English
Pages (from-to)	508-513
Number of pages	6
Journal	Brachytherapy
Volume	10
Issue number	6
DOIs	https://doi.org/10.1016/j.brachy.2011.04.002
State	Published - Nov 2011
Externally published	Yes

Keywords

Brachytherapy
Cesium-131
Head and Neck
I
Lung
Radiation

Access to Document

10.1016/j.brachy.2011.04.002

Cite this

Parashar, B., Wernicke, A. G., Pavese, A., Singh, P., Trichter, S., Sabbas, A., Kutler, D. I., Kuhel, W., Port, J. L., Lee, P. C., Nori, D., & Chao, K. S. C. (2011). Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff. Brachytherapy, 10(6), 508-513. https://doi.org/10.1016/j.brachy.2011.04.002

@article{4e6cb95a7d3248159dd782e24150561d,

title = "Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff",

abstract = "Purpose: Cesium-131 ( 131Cs) radioactive seed is Food and Drug Administration approved for permanent seed implant for all cancers, including lung and head and neck (HN) cancers. We describe the first clinical report of 131Cs dosimetry and exposure rates to treating physicians and staff. Methods and Materials: Twenty-eight patients received 131Cs implant for early stage lung and recurrent HN cancers. A nomogram was developed to calculate the number of seeds needed to cover the wedge line with the prescription dose (80Gy). Final dosimetry was obtained after CT planning a few days following the surgical procedure. Radiation exposure to the treating physicians and staff was measured at the completion of the procedure. Results: A nomogram was developed using the variseed software with source data from American Association of Physicists in Medicine TG-43 report. The total volume covered by the prescription isodose line of 131Cs was measured and compared with 125I. The prescription volume was smaller for 131Cs. In addition, the exposure rate with 131Cs was found to be acceptable. Conclusion: Our preliminary experience with 131Cs lung and HN brachytherapy has been very encouraging with excellent dosimetric coverage and acceptable exposure to the treating physicians and staff.",

keywords = "Brachytherapy, Cesium-131, Head and Neck, I, Lung, Radiation",

author = "Bhupesh Parashar and Wernicke, {A. Gabriella} and Al Pavese and Prabhsimranjot Singh and Samuel Trichter and Albert Sabbas and Kutler, {David I.} and William Kuhel and Port, {Jeffery L.} and Lee, {Paul C.} and Dattatreyudu Nori and Chao, {K. S.Clifford}",

year = "2011",

month = nov,

doi = "10.1016/j.brachy.2011.04.002",

language = "English",

volume = "10",

pages = "508--513",

journal = "Brachytherapy",

issn = "1538-4721",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Cesium-131 permanent seed brachytherapy

T2 - Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff

AU - Parashar, Bhupesh

AU - Wernicke, A. Gabriella

AU - Pavese, Al

AU - Singh, Prabhsimranjot

AU - Trichter, Samuel

AU - Sabbas, Albert

AU - Kutler, David I.

AU - Kuhel, William

AU - Port, Jeffery L.

AU - Lee, Paul C.

AU - Nori, Dattatreyudu

AU - Chao, K. S.Clifford

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: Cesium-131 ( 131Cs) radioactive seed is Food and Drug Administration approved for permanent seed implant for all cancers, including lung and head and neck (HN) cancers. We describe the first clinical report of 131Cs dosimetry and exposure rates to treating physicians and staff. Methods and Materials: Twenty-eight patients received 131Cs implant for early stage lung and recurrent HN cancers. A nomogram was developed to calculate the number of seeds needed to cover the wedge line with the prescription dose (80Gy). Final dosimetry was obtained after CT planning a few days following the surgical procedure. Radiation exposure to the treating physicians and staff was measured at the completion of the procedure. Results: A nomogram was developed using the variseed software with source data from American Association of Physicists in Medicine TG-43 report. The total volume covered by the prescription isodose line of 131Cs was measured and compared with 125I. The prescription volume was smaller for 131Cs. In addition, the exposure rate with 131Cs was found to be acceptable. Conclusion: Our preliminary experience with 131Cs lung and HN brachytherapy has been very encouraging with excellent dosimetric coverage and acceptable exposure to the treating physicians and staff.

AB - Purpose: Cesium-131 ( 131Cs) radioactive seed is Food and Drug Administration approved for permanent seed implant for all cancers, including lung and head and neck (HN) cancers. We describe the first clinical report of 131Cs dosimetry and exposure rates to treating physicians and staff. Methods and Materials: Twenty-eight patients received 131Cs implant for early stage lung and recurrent HN cancers. A nomogram was developed to calculate the number of seeds needed to cover the wedge line with the prescription dose (80Gy). Final dosimetry was obtained after CT planning a few days following the surgical procedure. Radiation exposure to the treating physicians and staff was measured at the completion of the procedure. Results: A nomogram was developed using the variseed software with source data from American Association of Physicists in Medicine TG-43 report. The total volume covered by the prescription isodose line of 131Cs was measured and compared with 125I. The prescription volume was smaller for 131Cs. In addition, the exposure rate with 131Cs was found to be acceptable. Conclusion: Our preliminary experience with 131Cs lung and HN brachytherapy has been very encouraging with excellent dosimetric coverage and acceptable exposure to the treating physicians and staff.

KW - Brachytherapy

KW - Cesium-131

KW - Head and Neck

KW - I

KW - Lung

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=80055068374&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2011.04.002

DO - 10.1016/j.brachy.2011.04.002

M3 - Article

C2 - 21640663

AN - SCOPUS:80055068374

SN - 1538-4721

VL - 10

SP - 508

EP - 513

JO - Brachytherapy

JF - Brachytherapy

IS - 6

ER -

Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff

Abstract

Keywords

Access to Document

Fingerprint

Cite this